Generate Biomedicines filed for an IPO days after dosing the first patient in Phase III with GB‑0895, an AI‑designed anti‑TSLP antibody for severe asthma. The company said proceeds will fund completion of two Phase III SOLAIRIA studies and further development in COPD, and it highlighted earlier Phase I safety and durable biomarker suppression. Generate has raised about $805 million privately and holds partnerships with Amgen and Novartis; management framed the move as scaling programmable biology from discovery to late‑stage development.